Herein, we screened for the first time the p53 phosphorylation patterns of 71 TP53‐intact primary CLL samples treated by two DNA‐damaging agents (fludarabine, doxorubicin) and studied the impact of DNA damage on the CLL transcriptome. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.